Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.37 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 5/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734091 | 0.87 | CYP11B2 (0.44) | CTSAXDHCYP11B2 | |
| SCHEMBL3683054 | 0.81 | MAP4K4 (0.46) | CYP11B2 | |
| SCHEMBL1606214 | 0.80 | CYP11B2 (0.44) | SCN10AXDHCYP11B2 | |
| SCHEMBL27830504 | 0.79 | KMO (0.38) | CTSACYP11B2 | |
| SCHEMBL27830505 | 0.75 | AOC3 (0.38) | CYP11B2 | |
| SCHEMBL1606382 | 0.72 | CYP11B2 (0.46) | CYP11B2 | |
| SCHEMBL1606182 | 0.71 | AOC3 (0.41) | CYP11B2 | |
| SCHEMBL12190139 | 0.70 | AOC3 (0.40) | CYP11B2 | |
| SCHEMBL1606509 | 0.69 | CYP11B2 (0.39) | CYP11B2 | |
| SCHEMBL14605240 | 0.69 | CYP11B2 (0.46) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307371-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | SCN10A 2710/4885CTSA 3020/4885XDH 227/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | SCN10A 2865/4885CTSA 3205/4885XDH 217/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | SCN10A 2865/4885CTSA 3205/4885XDH 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.